This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients
- Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
- Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
- Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
- The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy
- Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor Expressing Breast Carcinomas
- 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
- Dosimetry in Peptide Radionuclide Receptor Therapy: A Review
- Effect of Molecular Size of Pegylated Peptide on the Pharmacokinetics and Tumor Targeting in Lymphoma-Bearing Mice
- Cancer Therapy with Auger Electrons: Are We Almost There?
- Evaluation of an 111In-DOTA-Rhenium Cyclized {alpha}-MSH Analog: A Novel Cyclic-Peptide Analog with Improved Tumor-Targeting Properties
- Tumor Response After [90Y-DOTA0,Tyr3]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size
- 64Cu-TETA-Octreotide as a PET Imaging Agent for Patients with Neuroendocrine Tumors
- Peptide Receptor Imaging and Therapy